DKSH N/ CH0126673539 /
2024-08-30 5:31:58 PM | Chg. -0.20 | Volume | Bid5:40:00 PM | Ask5:40:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
68.00CHF | -0.29% | 106,669 Turnover: 7.26 mill. |
66.90Bid Size: 100 | 69.00Ask Size: 220 | 4.42 bill.CHF | 3.31% | 24.29 |
GlobeNewswire
08-15
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire
08-15
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimi...
GlobeNewswire
08-01
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Confere...
GlobeNewswire
07-22
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Euro...
GlobeNewswire
07-02
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Bi...
GlobeNewswire
07-01
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
GlobeNewswire
06-18
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD ...
GlobeNewswire
05-29
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
GlobeNewswire
05-21
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire
05-21
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a bios...
GlobeNewswire
05-21
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
GlobeNewswire
05-13
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (...
GlobeNewswire
04-30
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentratio...
GlobeNewswire
04-24
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimil...
GlobeNewswire
04-19
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable...